drugset / Trial / NCT05582850
DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, multicentre, open-label, dose-escalation study to determine a recommended phase 2 dose (RP2D) of DT-9081, followed by an expansion study of DT-9081 in participants with advanced, recurrent or metastatic solid tumours
Timeline
- Start
- 2022-11-24
- Primary completion
- 2025-04-08
- Completion
- 2025-04-08
Outcome
Outcome not reported
Stopped (Business): “The trial was terminated prematurely at the end of the dose-escalation based on Sponsor's strategic decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DT-9081 | Unknown | 25 mg | Oral |
| Subject | DT-9081 | Unknown | 50 mg | Oral |
| Subject | DT-9081 | Unknown | 100 mg | Oral |